Savara Inc (SVRA) Stock Analysis and Metrics

Savara

NASDAQ: SVRA

$5.51 ▼ -0.24 (-4.26%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.39 Bn

P/E-10.77

Div. Yield0.00

Total Debt (Qtr)30.07 Mn

Add ratio to table…

About

Savara Inc. is a clinical stage biopharmaceutical company focused on rare respiratory diseases. The company’s sole program is molgramostim inhalation solution, also known as MOLBREEVI, an investigational inhaled biologic that delivers recombinant human granulocyte macrophage colony stimulating factor. MOLBREEVI is in Phase 3 development for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease where surfactant accumulates in the alveoli. The drug is administered via a proprietary eFlow Nebulizer System supplied by PARI Pharma GmbH.

Savara Inc. does not currently generate product revenue because its only product candidate remains investigational and has not received regulatory approval. The company finances its operations through equity offerings, debt arrangements, and potential milestone payments from collaborative partners. No product sales are recorded at this stage of development.

The company operates through a single reportable segment that encompasses all research, development, and commercialization activities related to its investigational therapy.

• Savara Inc.: This segment includes the discovery, preclinical and clinical development, manufacturing, and regulatory work for molgramostim inhalation solution targeting autoimmune pulmonary alveolar proteinosis.

Savara Inc. occupies a niche position within the rare respiratory disease landscape as there are no approved pharmacologic therapies for autoimmune pulmonary alveolar proteinosis in the United States or the European Union. The company benefits from multiple regulatory incentives including Fast Track, Breakthrough Therapy, and Orphan Drug designations from the U. S. Food and Drug Administration, as well as Orphan Drug designation from the European Medicines Agency and Innovation Passport and Promising Innovative Medicine designations from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency. These designations provide potential advantages in development timelines, market exclusivity, and reduced fees. Competitors are limited; while an injectable form of granulocyte macrophage colony stimulating factor is approved in Japan for autoimmune pulmonary alveolar proteinosis, no inhaled formulation is approved in the United States or Europe, giving Savara a potential first mover advantage if its product gains approval. Based on epidemiological studies, the diagnosed prevalence of autoimmune pulmonary alveolar proteinosis is estimated at six to seven cases per million individuals in the United States, with comparable or higher rates reported in other regions, indicating a limited but defined patient population for a potential therapy.

The company serves patients diagnosed with autoimmune pulmonary alveolar proteinosis and the healthcare providers who treat them, including pulmonologists and specialty care centers. No specific customer names are disclosed in the filing. The company’s therapeutic approach targets adult patients living with this rare lung disease, and it engages with specialized treatment centers that have expertise in diagnosing and managing pulmonary alveolar proteinosis.

Investment Thesis

▲ Bull case

Savara's lead program MOLBREEVI has secured Priority Review from the FDA with a PDUFA target action date of August 22, 2026, and has received similar accelerated pathways in Europe and the UK, creating a high-probability near-term catalyst for approval that the market may be undervaluing given the company's $203 million cash position as of Q1 2026 and access to up to $150 million in non-dilutive capital upon approval, which de-risks commercialization funding needs and positions Savara to capture significant value in the untreated autoimmune PAP market where no therapies are currently approved in the U.S. or Europe. The Breakthrough Therapy, Fast Track, and Orphan Drug designations across major regulatory agencies underscore the unmet medical need and clinical validity of MOLBREEVI, while the exclusivity period granted by Orphan Drug status in the U.S. (7 years) and Europe (10 years) provides a durable competitive moat that could support premium pricing and strong long-term revenue potential once launched, especially considering the estimated prevalence of autoimmune PAP in the U.S. and EU combined exceeds 10,000 diagnosed patients.
Recent clinical data from the IMPALA-2 Phase 3 trial presented at ATS 2026 demonstrate consistent and sustained improvements in key efficacy endpoints, including pulmonary gas transfer (DLco%), exercise capacity (distance and duration), and health-related quality of life (SGRQ scores), with long-term open-label data showing a 94% patient retention rate over 48 weeks and no discontinuations due to treatment-related adverse events, reinforcing the durability of effect and favorable safety profile of molgramostim; these results address a critical unspoken concern in rare disease therapeutics—long-term tolerability—and suggest that MOLBREEVI could achieve strong real-world adherence and persistence, which is often a limiting factor in chronic inhaled therapies, thereby increasing the likelihood of commercial success beyond initial launch.
The exclusive U.S. distribution agreement with PANTHERx Rare Pharmacy, a leader in rare disease patient support with a proven model achieving 95.45% resolution of barriers in patient assessments, represents an underappreciated value driver that goes beyond simple drug distribution to encompass comprehensive care coordination, financial assistance, and therapy education—factors that are particularly impactful in autoimmune PAP where patients face significant diagnostic delays and treatment burdens; this partnership could accelerate market penetration, improve reimbursement outcomes, and enhance patient satisfaction, potentially leading to faster uptake and stronger commercial performance than peers relying on traditional specialty pharmacy models, especially given Savara’s stated goal of delivering a “complete care experience” that aligns with evolving payer preferences for integrated rare disease solutions.

Savara's lead program MOLBREEVI has secured Priority Review from the FDA with a PDUFA target action date of August 22, 2026, and has received similar accelerated pathways in Europe and the UK, creating a high-probability near-term catalyst for approval that the market may be undervaluing given the company's $203 million cash position as of Q1 2026 and access to up to $150 million in non-dilutive capital upon approval, which de-risks commercialization funding needs and positions Savara to capture significant value in the untreated autoimmune PAP market where no therapies are currently approved in the U.S. or Europe. The Breakthrough Therapy, Fast Track, and Orphan Drug designations across major regulatory agencies underscore the unmet medical need and clinical validity of MOLBREEVI, while the exclusivity period granted by Orphan Drug status in the U.S. (7 years) and Europe (10 years) provides a durable competitive moat that could support premium pricing and strong long-term revenue potential once launched, especially considering the estimated prevalence of autoimmune PAP in the U.S. and EU combined exceeds 10,000 diagnosed patients.
Recent clinical data from the IMPALA-2 Phase 3 trial presented at ATS 2026 demonstrate consistent and sustained improvements in key efficacy endpoints, including pulmonary gas transfer (DLco%), exercise capacity (distance and duration), and health-related quality of life (SGRQ scores), with long-term open-label data showing a 94% patient retention rate over 48 weeks and no discontinuations due to treatment-related adverse events, reinforcing the durability of effect and favorable safety profile of molgramostim; these results address a critical unspoken concern in rare disease therapeutics—long-term tolerability—and suggest that MOLBREEVI could achieve strong real-world adherence and persistence, which is often a limiting factor in chronic inhaled therapies, thereby increasing the likelihood of commercial success beyond initial launch.
The exclusive U.S. distribution agreement with PANTHERx Rare Pharmacy, a leader in rare disease patient support with a proven model achieving 95.45% resolution of barriers in patient assessments, represents an underappreciated value driver that goes beyond simple drug distribution to encompass comprehensive care coordination, financial assistance, and therapy education—factors that are particularly impactful in autoimmune PAP where patients face significant diagnostic delays and treatment burdens; this partnership could accelerate market penetration, improve reimbursement outcomes, and enhance patient satisfaction, potentially leading to faster uptake and stronger commercial performance than peers relying on traditional specialty pharmacy models, especially given Savara’s stated goal of delivering a “complete care experience” that aligns with evolving payer preferences for integrated rare disease solutions.

▼ Bear case

Despite the positive regulatory momentum, Savara remains a pre-revenue clinical-stage company with a history of persistent losses, reporting a net loss of $37.3 million in Q1 2026 and $118.8 million for FY 2025, driven largely by escalating R&D and G&A expenses tied to the MOLBREEVI program; the company’s reliance on a single product candidate for near-term value creation creates significant binary risk, as any delay or setback in the FDA’s review—despite the Priority Review designation—could trigger a sharp repricing of the stock, particularly given that the PDUFA date has already been subject to scrutiny and potential extension, and the market may be underestimating the probability of a complete response letter (CRL) due to unresolved chemistry, manufacturing, and controls (CMC) questions, which were cited as a driver of increased R&D costs in recent quarters.
The autoimmune PAP patient population, while suffering from a debilitating condition, is extremely small and geographically dispersed, with estimates suggesting fewer than 5,000 diagnosed patients in the U.S. and a similar number in Europe, raising concerns about the commercial viability of MOLBREEVI even if approved; the cost of developing and launching a specialized inhaled therapy with a proprietary nebulizer system may not be justified by the limited addressable market, especially when considering the need for patient education, diagnostic infrastructure buildup, and reimbursement negotiation in a disease area with no established standard of care, which could lead to slow adoption and underwhelming launch trajectory despite positive clinical data.
Savara’s increasing dependence on equity-based compensation, evidenced by $7.8 million in PSU-related expenses in Q1 2026 alone and a significant uptick in share-based pay across R&D and G&A functions, signals potential dilution pressure and misalignment of long-term incentives, as the company continues to issue inducement awards (such as the April 2026 grant covering 244,500 shares to new employees) despite a stagnant share price and ongoing cash burn; this trend, combined with a growing fully diluted share base exceeding 253 million shares, could erode shareholder value over time, particularly if commercial execution falters and the company needs to return to the capital markets for additional funding, creating a scenario where upside from approval is partially offset by persistent dilution and weak operating leverage.

Despite the positive regulatory momentum, Savara remains a pre-revenue clinical-stage company with a history of persistent losses, reporting a net loss of $37.3 million in Q1 2026 and $118.8 million for FY 2025, driven largely by escalating R&D and G&A expenses tied to the MOLBREEVI program; the company’s reliance on a single product candidate for near-term value creation creates significant binary risk, as any delay or setback in the FDA’s review—despite the Priority Review designation—could trigger a sharp repricing of the stock, particularly given that the PDUFA date has already been subject to scrutiny and potential extension, and the market may be underestimating the probability of a complete response letter (CRL) due to unresolved chemistry, manufacturing, and controls (CMC) questions, which were cited as a driver of increased R&D costs in recent quarters.
The autoimmune PAP patient population, while suffering from a debilitating condition, is extremely small and geographically dispersed, with estimates suggesting fewer than 5,000 diagnosed patients in the U.S. and a similar number in Europe, raising concerns about the commercial viability of MOLBREEVI even if approved; the cost of developing and launching a specialized inhaled therapy with a proprietary nebulizer system may not be justified by the limited addressable market, especially when considering the need for patient education, diagnostic infrastructure buildup, and reimbursement negotiation in a disease area with no established standard of care, which could lead to slow adoption and underwhelming launch trajectory despite positive clinical data.
Savara’s increasing dependence on equity-based compensation, evidenced by $7.8 million in PSU-related expenses in Q1 2026 alone and a significant uptick in share-based pay across R&D and G&A functions, signals potential dilution pressure and misalignment of long-term incentives, as the company continues to issue inducement awards (such as the April 2026 grant covering 244,500 shares to new employees) despite a stagnant share price and ongoing cash burn; this trend, combined with a growing fully diluted share base exceeding 253 million shares, could erode shareholder value over time, particularly if commercial execution falters and the company needs to return to the capital markets for additional funding, creating a scenario where upside from approval is partially offset by persistent dilution and weak operating leverage.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Business Acquisition Breakdown of Revenue (2017)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Business Acquisition Breakdown of Revenue (2017)

Peer Comparison

Create an account

Sign In

Reset Password